SCHEMBL4473339

SCHEMBL4473339

Cc1[nH]c(C)c(-c2cnc(-c3ccc(OC(F)(F)F)cc3)nc2)c(=O)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.41
SCN10A Q9Y5Y9 6/20 0.39
KCNH2 Q12809 4/20 0.39
SCN1A P35498 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN8A Q9UQD0 1/20 0.39
TDP2 O95551 1/20 0.37
NOTUM Q6P988 1/20 0.36
MAT2A P31153 1/20 0.36
CASP3 P42574 1/20 0.36
PTGS2 P35354 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PSD A5PKW4 1/20 0.36
CHRNA7 P36544 1/20 0.35
KIF11 P52732 1/20 0.35
NPY5R Q15761 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490712 0.87 SLC2A1 (0.40) SLC2A1SCN10AKCNH2SCN1ASCN5A
Hydrochloric Acid SCHEMBL4489660 0.86 DGAT1 (0.39) SLC2A1SCN10AKCNH2SCN1ASCN5A
SCHEMBL4481797 0.85 SLC2A1 (0.44) SLC2A1SCN10AKCNH2SCN1ASCN5A
SCHEMBL4492260 0.84 SLC2A1 (0.41) SLC2A1KCNH2SCN2ATDP2
SCHEMBL4472453 0.84 SLC2A1 (0.58) SLC2A1SCN10AKCNH2SCN1ASCN5A
SCHEMBL4476493 0.82 SLC2A1 (0.52) SLC2A1SCN10AKCNH2SCN1ASCN5A
SCHEMBL4471107 0.78 XDH (0.45) SLC2A1SCN10AKCNH2NPY5R
SCHEMBL3713576 0.77 SLC2A1 (0.42) SLC2A1
SCHEMBL3712620 0.76 SLC2A1 (0.41) SLC2A1KIF11
Hydrochloric Acid SCHEMBL3398480 0.76 SLC2A1 (0.41) SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885SCN10A 3578/4885KCNH2 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.